Long-term safety and effectiveness of eculizumab in patients with AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance

被引：0

作者：

Nakahara, Jin ^{[1
]}

Nakashima, Ichiro ^{[2
]}

Yokote, Hiroaki ^{[3
]}

Manabe, Yasuhiro ^{[4
]}

Okamura, Kazumi ^{[5
]}

Hasegawa, Kou ^{[5
]}

Fujihara, Kazuo ^{[6
,7
]}

机构：

[1] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan

[2] Tohoku Med & Pharmaceut Univ, Div Neurol, Sendai, Japan

[3] Tokyo Metropolitan Komagome Hosp, Dept Neurol, Tokyo, Japan

[4] Natl Hosp Org Okayama Med Ctr, Dept Neurol, Okayama, Japan

[5] Alexion Pharma GK, Tokyo, Japan

[6] Fukushima Med Univ, Fukushima, Japan

[7] Southern TOHOKU Res Inst Neurosci STRINS, Koriyama, Japan

来源：

MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P010/1870

引用

页码：144 / 144

页数：1

共 50 条

[21] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
Tanaka, Sakae
Mizutani, Hideki
Tsuruya, Eri
Fukuda, Ryoko
Kuge, Kiyoka
Okubo, Naoki
JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (03) : 463 - 473
[22] Long-term safety and effectiveness of omalizumab in Japanese paediatric patients with severe allergic asthma: A post-marketing surveillance
Nakamura, N.
Kashitani, Y.
Yoshisue, H.
Nagasaki, M.
Sasajima, T.
ALLERGY, 2020, 75 : 364 - 365
[23] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
Murai, Hiroyuki
Suzuki, Shigeaki
Hasebe, Miki
Fukamizu, Yuji
Rodrigues, Ema
Utsugisawa, Kimiaki
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
[24] Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
Kenichi Namba
Toshikatsu Kaburaki
Hidekazu Tsuruga
Yohei Ogawa
Eri Iwashita
Hiroshi Goto
Ophthalmology and Therapy, 2022, 11 : 1147 - 1161
[25] Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
Namba, Kenichi
Kaburaki, Toshikatsu
Tsuruga, Hidekazu
Ogawa, Yohei
Iwashita, Eri
Goto, Hiroshi
OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 1147 - 1161
[26] Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance
Yamaguchi, Hiromi
Shimatsu, Akira
Okayama, Akifumi
Sato, Takahiro
ENDOCRINE JOURNAL, 2020, 67 (02) : 201 - 210
[27] Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance
Hitoshi Nagura
Jiro Hokugo
Kazuo Ueda
Neurology and Therapy, 2019, 8 : 397 - 409
[28] Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance
Nagura, Hitoshi
Hokugo, Jiro
Ueda, Kazuo
NEUROLOGY AND THERAPY, 2019, 8 (02) : 397 - 409
[29] Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder
Wingerchuk, Dean
Berthele, Achim
Fujihara, Kazuo
Oreja-Guevara, Celia
Kim, Ho Jin
Levy, Michael
Nakashima, Ichiro
Palace, Jacqueline
Shang, Shulian
Yountz, Marcus
Miller, Larissa
Pittock, Sean
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
[30] Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease
Barreras, Paula
Vasileiou, Eleni S.
Filippatou, Angeliki G.
Fitzgerald, Kathryn C.
Levy, Michael
Pardo, Carlos A.
Newsome, Scott D.
Mowry, Ellen M.
Calabresi, Peter A.
Sotirchos, Elias S.
NEUROLOGY, 2022, 99 (22) : E2504 - E2516

← 1 2 3 4 5 →